Misleading high tobramycin plasma concentrations can be caused by skin contamination of fingerprick blood following inhalation of nebulized tobramycin (TOBI®): A short report

Therapeutic Drug Monitoring

Volumn 27, Issue 2, 2005, Pages 205-207

  Redmann, Stefanie ^a,b   Wainwright, Claire ^b   Stacey, Sonya ^b   Champion, Anita ^b   Mitchell, Penny ^b   Cheney, Joyce ^b   Charles, Bruce ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c MATER CHILDREN S HOSPITAL   (Australia)

Author keywords

Blood sampling; Cystic fibrosis; Fingerprick; Skin contamination; Tobramycin nebulization

Indexed keywords

TOBRAMYCIN;

ARTICLE; BLOOD SAMPLING; CASE REPORT; CYSTIC FIBROSIS; DRUG MONITORING; FEMALE; HUMAN; MALE; NEBULIZATION; PRESCHOOL CHILD; PRIORITY JOURNAL; VEIN PUNCTURE;

CHILD, PRESCHOOL; DRUG CONTAMINATION; FALSE POSITIVE REACTIONS; FEMALE; FINGERS; HUMANS; INHALATION; MALE; NEBULIZERS AND VAPORIZERS; PHLEBOTOMY; SKIN; SKIN ABSORPTION; TOBRAMYCIN;

EID: 16244415901     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000155341.16361.62     Document Type: Article

References (15)

1. Nixon G, Armstrong D, Carzino R, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Paediatr. 2001; 138:699-704.
2. Le Brun PPH, de Boer AH, Gjaltema D, et al. Inhalation of tobramycin in cystic fibrosis. Part 1: The choice of a nebulizer. Int J Pharm. 1999;189: 205-214.
3. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med. 2003;167:841-849.
4. Wainwright C, Carlin J, Cooper P. Early infections with Pseudomonas can be cleared in young children with cystic fibrosis. Pediatr Pulmonol. 2002; 524:300.
5. Ramsey BW, Dorkin H, Eisenberg J, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med. 1993;328:1740-1746.
6. Rosenfeld M, Gibson RL, McNamara S, et al. Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. J Pediatr. 2001;139:572-577.
7. Bentur Y, Hummel D, Roifman CM, et al. Interpretation of excessive levels of inhaled tobramycin. Ther Drug Monit. 1989;11:109-110.
8. Elidemir O, Maciejewski SR, Oermann CM. Falsely elevated serum tobramycin concentrations in cystic fibrosis patients treated with concurrent intravenous and inhaled tobramycin. Pediatr Pulmonol. 2000;29:43-45.
9. Donnelly R, Seale JP. Clinical pharmacokinetics of inhaled budesonide. Clin Pharmacokinet. 2001;40:427-440.
10. Agertoft L, Anderson A, Weilbull E, et al. Systemic availability and pharmacokinetics of nebulized budesonide in preschool children. Arch Dis Child. 1999;80:241-247.
11. Janson C, Herala M. Plasma terbutaline levels in nebulisation treatment of acute asthma. Pulm Pharmacol. 1991;4:135-139.
12. Lewis LD, McLaren M, Essex E, et al. Plasma concentrations of salbutamol in acute severe asthmatics. Aust N Z J Med. 1990;20:204-207.
13. Ramsey BW, Pepe M, Quan J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999;340: 23-30.
14. Cooney GF, Lum BL, Tomaselli M, et al. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J Clin Pharmacol. 1994;34:255-259.
15. Pai VB, Nahata MC. Efficacy and safety of aerosolized tobramycin in cystic fibrosis. Pediatr Pulmonol. 2001;32:314-327.